Drugs / nL-GARS1-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07226297 | Oct 2025 → Oct 2027 expected | Charcot-Marie-Tooth disease type 2D | n-Lorem Foundation | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nL-GARS1-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226297 ↗ |
| Modality | Antisense oligonucleotide | “Personalized antisense oligonucleotide” NCT07226297 ↗ |